Vanda Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. The Company’s product portfolio includes: HETLIOZ (tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24); Fanapt (iloperidone), a product for the treatment of schizophrenia, the oral formulation; and VLY-686 (tradipitant), a small molecule neurokinin-1 receptor (NK-1R) antagonist. . Novartis has exclusive commercialization rights to all formulations of Fanapt in the United States and Canada. Novartis is responsible for the further clinical development activities in the United States and Canada.